celltrion
Celltrion opens new UK headquarters in Uxbridge to drive long-term growth
June 19, 2025Research and Development Corporate, Pharmacy, biosimilar medicines, celltrion
Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, …
Celltrion launches Humira biosimilar in US
July 7, 2023Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion
South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …
Experimental COVID antibody treatment successful in trials
June 14, 2021Sales and Marketing COVID-19, antibody therapy, celltrion, phase III
Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III trials finding it safe and …
Celltrion’s COVID-19 treatment shows promise against South African variant
April 30, 2021Medical Communications COVID-19, celltrion, covid 19 news, covid-19 news, covid-19 treatment, pharma, pharma news
Celltrion’s regdanvimab treatment for COVID-19 has shown itself to be effective against the South African variant of the virus, according …
Celltrion’s inflammatory disease drug Yuflyma gets EU approval for 13 indications
February 16, 2021Manufacturing and Production EC, celltrion
The European Commission (EC) has granted marketing authorisation for Celltrion’s Yuflyma, an adalimumab biosimilar, across all thirteen intended indications for …
South Korea approves Celltrion’s COVID-19 treatment Regdanvimab for emergency use
February 8, 2021Sales and Marketing COVID-19, celltrion
The South Korean Ministry of Food and Drug Safety (MFDS) has granted a conditional marketing authorisation (CMA) for the emergency …
Celltrion announces positive top-line results from COVID-19 treatment trial
January 14, 2021COVID-19, celltrion
Celltrion Group has announced that top-line results from its global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody …
Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis
November 4, 2020Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis
Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …
Celltrion’s infliximab biosimilar Remsima secures European approval in five indications
July 27, 2020Manufacturing and Production, Sales and Marketing celltrion, infliximab, pharma, remsima
The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from the European Commission covering five …
Takeda jettisons non-core portfolio in Asia Pacific to Celltrion for a potential $278 million
June 12, 2020Medical Communications, Sales and Marketing Takeda, celltrion, pharma, sale
Takeda continues its mission to reduce its debt in the wake of its $49 billion acquisition of Shire in January …
FDA greenlights Celltrion HIV drug manufacturing facility in South Korea
March 16, 2020Manufacturing and Production, Sales and Marketing FDA, celltrion, coronavirus, pharma
South Korean biopharma firm Celltrion has revealed that one of its key manufacturing facilities has been given the all-clear by …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation
September 24, 2019Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer
December 18, 2018Manufacturing and Production, Sales and Marketing Herceptin, Herzuma, Teva, celltrion, pharma
Israeli and South Korean-based drug makers Teva and Celltrion are set to move in on the market share occupied by …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
